Melissa Miara, DO
Pulmonary Disease · Loris, SCNPI 1801231634
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $10,241 of the $14,274 with a category attached, or 71.7%. It is spread thinly across 37 manufacturers, the largest accounting for just 22.7%. 2025 is the largest year on record at $3,989, 5.0 times the $806 reported in 2019.
Across 483 payments — averaging $29.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$3K
- AstraZeneca$2K
- GSK$1K
- Insmed, Inc.$1K
- Veran Medical Technologies, Inc.$975
- Boehringer Ingelheim$964
- plus $5K from 31 others
What the payments were for
- Consulting fees$380%
- Travel & lodging$2,05214%
- Food & beverage$10,24172%
- Education$1,94314%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 14 | $3,235 |
| AstraZeneca | 74 | $1,582 |
| GSK | 77 | $1,218 |
| Insmed, Inc. | 43 | $1,171 |
| Veran Medical Technologies, Inc. | 2 | $975 |
| Boehringer Ingelheim | 41 | $964 |
| Sanofi | 22 | $703 |
| Actelion Pharmaceuticals US, Inc. | 36 | $561 |
| United Therapeutics Corporation | 13 | $502 |
| Mallinckrodt Hospital Products Inc. | 17 | $387 |
| Mylan Specialty L.p. | 20 | $351 |
| Regeneron Healthcare Solutions, Inc. | 15 | $346 |
| Merck | 15 | $330 |
| Grifols USA, LLC | 12 | $283 |
| Amgen | 10 | $240 |
| Baxter Healthcare | 11 | $194 |
| Philips North America LLC | 8 | $154 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $139 |
| Electromed, Inc. | 10 | $116 |
| Sanofi-aventis U.S. LLC | 1 | $97 |
| Pfizer | 5 | $92 |
| Verona Pharma, Inc. | 3 | $78 |
| Harmony Biosciences LLC | 3 | $77 |
| Advanced Respiratory, Inc | 4 | $74 |
| Teva Pharmaceuticals USA, Inc. | 4 | $62 |
| Inspire Medical Systems, Inc. | 2 | $60 |
| Viatris Specialty LLC | 3 | $56 |
| ADMA Biomanufacturing LLC | 1 | $38 |
| Genentech USA, Inc. | 2 | $37 |
| Gilead | 2 | $35 |
| Johnson & Johnson | 2 | $24 |
| ANI Pharmaceuticals, Inc. | 1 | $18 |
| Vapotherm Inc | 1 | $17 |
| Novartis | 1 | $17 |
| Astellas Pharma US Inc | 1 | $17 |
| Circassia Inc. | 1 | $15 |
| Nabriva Therapeutics, PLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$3,058
- Spin$964
- FASENRA$125
- DUPIXENT$115
How this compares
$14,274 in reported general payments places this provider in the 80th percentile of 192 pulmonary disease providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 618 | $574,808 |
| Tyvaso DpiTreprostinil | 12 | $276,498 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 178 | $172,545 |
| AdempasRiociguat | 12 | $169,323 |
| Dupixent PenDupilumab | 26 | $114,680 |
| Breo ElliptaFluticasone/Vilanterol | 164 | $88,578 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 89 | $76,224 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 94 | $62,832 |
| TezspireTezepelumab-Ekko | 15 | $61,927 |
| SymbicortBudesonide/Formoterol Fumarate | 63 | $21,789 |
| Spiriva RespimatTiotropium Bromide | 28 | $21,327 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 463 | $16,907 |
| Incruse ElliptaUmeclidinium Bromide | 12 | $10,682 |
| Wixela InhubFluticasone Propion/Salmeterol | 51 | $9,503 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 46 | $8,497 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta | $1,218 | $741,948905 claims |
| AstraZenecaBreztri Aerosphere, Tezspire, Symbicort | $1,582 | $256,261256 claims |
| Boehringer IngelheimStiolto Respimat, Spiriva Respimat | $964 | $97,550117 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 192 pulmonary disease providers in South Carolina.
Other pulmonary disease in Loris
- Abhijit RavalAnderson$2M
- Richard BoganColumbia$1.1M
- Joseph BosciaSpartanburg$701K
- Patrick FlumeCharleston$418K
- Sean CallahanGreenville$321K
- Laura HerpelColumbia$254K
- Gerard SilvestriCharleston$254K
- Arun AdlakhaRock Hill$184K
- Jake KriegmdColumbia$112K
- Mark MaysonColumbia$86K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.